These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination. Ohno S; Takano F; Ohta Y; Kyo S; Myojo S; Dohi S; Sugiyama H; Ohta T; Inoue M Anticancer Res; 2011 Jul; 31(7):2447-52. PubMed ID: 21873158 [TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy targeting WT1 protein. Sugiyama H Int J Hematol; 2002 Aug; 76(2):127-32. PubMed ID: 12215010 [TBL] [Abstract][Full Text] [Related]
10. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. Koido S; Okamoto M; Shimodaira S; Sugiyama H Immunotherapy; 2016 Nov; 8(11):1309-1320. PubMed ID: 27993090 [TBL] [Abstract][Full Text] [Related]
11. HLA-restricted presentation of WT1 tumor antigen in B-lymphoblastoid cell lines established using a maxi-EBV system. Kanda T; Ochi T; Fujiwara H; Yasukawa M; Okamoto S; Mineno J; Kuzushima K; Tsurumi T Cancer Gene Ther; 2012 Aug; 19(8):566-71. PubMed ID: 22722376 [TBL] [Abstract][Full Text] [Related]
12. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Van Driessche A; Berneman ZN; Van Tendeloo VF Oncologist; 2012; 17(2):250-9. PubMed ID: 22291091 [TBL] [Abstract][Full Text] [Related]
13. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker. Roberts DJ; Haber D; Sklar J; Crum CP Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523 [TBL] [Abstract][Full Text] [Related]
14. Wilms' tumor 1 (WT1) as a prognosis factor in gynecological cancers: A meta-analysis. Lu J; Gu Y; Li Q; Zhong H; Wang X; Zheng Z; Hu W; Wen L Medicine (Baltimore); 2018 Jul; 97(28):e11485. PubMed ID: 29995811 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy. Schillingmann DA; Riese SB; Vijayan V; Tischer-Zimmermann S; Schmetzer H; Maecker-Kolhoff B; Blasczyk R; Immenschuh S; Eiz-Vesper B Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678050 [TBL] [Abstract][Full Text] [Related]
16. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Tsuboi A; Oka Y; Osaki T; Kumagai T; Tachibana I; Hayashi S; Murakami M; Nakajima H; Elisseeva OA; Fei W; Masuda T; Yasukawa M; Oji Y; Kawakami M; Hosen N; Ikegame K; Yoshihara S; Udaka K; Nakatsuka S; Aozasa K; Kawase I; Sugiyama H Microbiol Immunol; 2004; 48(3):175-84. PubMed ID: 15031530 [TBL] [Abstract][Full Text] [Related]